Should I Buy LEXX? LEXX 2026 Analysis

Should You Buy Lexaria Bioscience Corp (LEXX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.760

1 Day change

-1.80%

52 Week Range

1.910

Analysis Updated At

2026/01/26

Lexaria Bioscience Corp (LEXX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The company's financial performance is weak, with significant revenue and net income declines, and the technical indicators do not suggest a compelling entry point. Additionally, there are no strong positive catalysts or proprietary trading signals to justify immediate action.

Technical Analysis

The MACD histogram is positive and expanding, suggesting a bullish momentum. However, the RSI is in the neutral zone at 71.836, and moving averages are converging, indicating no strong trend. The stock is trading near its resistance level (R1: 0.842), which could limit upside potential in the short term.

Options Data

Positive Catalysts

The company has reported some progress in its DehydraTECH-semaglutide technology, reducing side effects compared to Rybelsus. Additionally, the global energy drinks market is projected to grow, which could indirectly benefit the company through its subsidiary's wellness-focused offerings.

Neutral/Negative Catalysts

The company's financial performance is weak, with revenue dropping to zero and net income down significantly. Analyst Yi Chen has lowered the price target from $4 to $1.50, citing less robust performance in body weight reduction compared to competitors. There are no significant insider or hedge fund trading trends, and the stock has a high probability of short-term decline based on candlestick pattern analysis.

Financial Performance

In Q1 2026, revenue dropped to 0 (-100% YoY), net income declined to -$1,595,007 (-41.01% YoY), and EPS fell to -0.14 (-12.50% YoY). Gross margin increased slightly to 100 (+1.50% YoY), but overall financials indicate poor performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright analyst Yi Chen maintains a Buy rating but has lowered the price target from $4 to $1.50 due to less robust performance in body weight reduction compared to competitors. This reflects tempered optimism about the company's growth prospects.

1 Analyst Rating

Wall Street analysts forecast LEXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is 1.5 USD with a low forecast of 1.5 USD and a high forecast of 1.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.778

Low

1.5

Averages

1.5

High

1.5

Current: 0.778

Low

1.5

Averages

1.5

High

1.5

H.C. Wainwright

Yi Chen

Buy

downgrade

AI Analysis

2025-12-26

Reason

H.C. Wainwright

Yi Chen

Price Target

AI Analysis

2025-12-26

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Lexaria Bioscience to $1.50 from $4 and keeps a Buy rating on the shares after the company reported final results from the Phase 1b GLP-1-H24-4 study recently completed in Australia. DehydraTECH-semaglutide reduced overall side-effects by 48% compared to Rybelsus, but performance in body weight reduction was not as robust as Rybelsus, the analyst tells investors in a research note.

H.C. Wainwright

Yi Chen

Buy

downgrade

$5 -> $4

2025-07-29

Reason

H.C. Wainwright

Yi Chen

Price Target

$5 -> $4

2025-07-29

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Lexaria Bioscience to $4 from $5 and keeps a Buy rating on the shares after the company reported interim results from the Phase 1b GLP-1-H24-4 study currently underway in Australia. The firm says DehydraTECH-semaglutide has demonstrated a favorable safety and tolerability profile.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LEXX

Unlock Now

LEXX Should I Buy

LEXX Should I Buy

Should You Buy Lexaria Bioscience Corp (LEXX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch